AAV Tropism for Ear and Inner Ear Tissues

Gene therapy for the ear (specifically the inner ear) focuses on the Cochlea for hearing and the Vestibular System for balance. Because the inner ear is encased in dense bone and filled with delicate fluids, delivery is usually achieved through a local injection via the Round Window Membrane (RWM) or a Cochleostomy.

A major challenge in the ear is that while many AAVs easily target Inner Hair Cells (IHCs), very few natural serotypes effectively reach Outer Hair Cells (OHCs), which are essential for sound amplification.

Serotype	Primary Cell Target	Tropism Level	Best Use Case	Notes
AAV2	IHCs, SGNs, SCs	High (IHCs)	General hearing loss	One of the most studied; targets almost 100% of Inner Hair Cells (IHCs) but has variable success with OHCs.
AAV1	IHCs	High	IHC-specific defects	Excellent at targeting IHCs; used in several successful mouse models for genetic deafness.
AAV8	IHCs, Vestibular HCs	High	Balance & Hearing	Safe and efficient for IHCs and vestibular hair cells; minimal risk of damaging hearing during injection.
AAV9	IHCs, SGNs	Moderate/High	Spiral Ganglion targeting	Broad tropism; good for targeting the neurons (SGNs) that carry sound signals to the brain.
Anc80L65	IHCs & OHCs	Ultra High	Full auditory restoration	Synthetic “ancestral” AAV; the first to show high-efficiency (nearly 100%) transduction of both IHCs and OHCs.
AAV-S	IHCs & OHCs	Ultra High	Primates & Rodents	A newer synthetic variant that targets nearly all cell types in the organ of Corti across species.
AAV-PHP.B	IHCs, SCs	High	Systemic or CSF delivery	Can reach the ear via the cerebrospinal fluid (CSF) or blood, though less efficient than direct local injection.

Key Targets in the Ear

• Inner Hair Cells (IHCs): The actual sensory cells that send sound signals to the brain. Most AAVs (1, 2, 8) target these well.
• Outer Hair Cells (OHCs): The “amplifiers.” Very difficult to target with natural AAVs. Anc80L65 and AAV-S are the current leaders for OHC targeting.
• Spiral Ganglion Neurons (SGNs): The nerves that connect the ear to the brain. Important for cases where hair cells are dead and the nerve needs to be kept alive (e.g., to improve Cochlear Implant success).
• Supporting Cells (SCs): Cells surrounding the hair cells. These are often targets for “regenerative” therapy, where researchers try to turn SCs into new hair cells.

Delivery Methods for the Ear

The physical barrier of the ear means “how” you inject is just as important as the serotype:

1. Round Window Membrane (RWM) Injection: The most common clinical route. The virus is injected through a thin membrane into the fluid of the cochlea.
2. Canalostomy: Injecting through the semicircular canals of the vestibular system. This allows the virus to flow into the cochlea and is often used in adult animal models to avoid hearing loss.
3. Cochleostomy: Making a small hole directly in the bony shell of the cochlea. This is highly effective but carries a higher risk of causing permanent hearing damage.

Promoters for Ear Specificity

To ensure your gene only turns on in specific ear cells:

• Myo7a: A common promoter used for all Hair Cells (IHCs and OHCs).
• Atoh1: Often used for Hair Cell regeneration experiments.
• GFAP: Used to target Supporting Cells.